Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target

Endocrine Practice

Volumn 14, Issue 5, 2008, Pages 618-624

  Vetter, Marion L ^a   Kaul, Shailja ^a   Iqbal, Nayyar ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LEVOTHYROXINE; NILOTINIB; PANITUMUMAB; SORAFENIB; SUNITINIB; THYROID HORMONE; TRASTUZUMAB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; THYROXINE;

BREAST CANCER; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLEARANCE; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DYSPEPSIA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEART EJECTION FRACTION; HISTIOCYTOMA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MONITORING; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; PANCREAS CANCER; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; SYSTEMIC MASTOCYTOSIS; THYROID FUNCTION TEST; THYROID GLAND; THYROID HORMONE SYNTHESIS; THYROIDITIS; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY;

HUMANS; HYPOTHYROIDISM; INDOLES; PROTEIN KINASE INHIBITORS; PYRROLES; THYROID FUNCTION TESTS; THYROID GLAND; THYROXINE;

EID: 58149463969     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.5.618     Document Type: Review

References (35)

1. Krause D, Van Etten E. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.
2. Tyrosine kinase overview: enzyme explorer. St. Louis, MO: Sigma-Aldrich, Inc, 2008. http://www.sigmaaldrich.com/Area-of-Interest/Biochemicals/Enzyme- Explorer/Key-Resources/Protein-Kinase-Explorer/Tyrosine-Kinase-Overview.html. Accessed for verification June 5, 2008.
3. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753-764.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
6. Myllärniemi M, Calderon L, Lemström K, Buchdunger E, Häyry P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 1997;11:1119-1126.
7. Goodsell DS. The molecular perspective: epidermal growth factor. Oncologist. 2003;8:496-497.
8. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677-685.
9. Drug information summaries. Bethesda, MD: National Cancer Institute, U.S. National Institutes of Health, 2008. http://www.cancer.gov/cancertopics/ druginfo/alphalist. Accessed for verification June 5, 2008.
10. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107-113.
11. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896.
12. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61:515-524.
13. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-916.
14. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.
15. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med. 2006;145:702-703.
16. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019.
17. Schoeffski P, Wolter P, Himpe U, et al. Sunitinib related thyroid dysfunction: a single-center retrospective and prospective evaluation [abstract]. J Clin Oncol. 2006;24 (18S):143S.
18. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-83.
19. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351-355.
20. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-664.
21. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-3534.
22. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005;78:433-438.
23. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19:265-268.
24. Surks M, Sievert R. Drugs and thyroid function. N Engl J Med. 1995;33:1688-1694.
25. Schultz M, Müller R, von zur Mühlen A, Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet. 1989;1:1452.
26. Primo J, Hinojosu J, Molés JR, et al. Development of thyroid dysfunction after alpha-interferon treatment for chronic hepatitis C. Am J Gastroenterol. 1993;88:1976-1977.
27. Schwartzentruber DJ, White DE, Zweig MH, Weintraub BD, Rosenberg SA. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer. 1991;68:2384-2390.
28. Pearce EN, Farwell AP, Braverman LE. Thyroiditis [published correction appears in N Engl J Med. 2003;349: 620]. N Engl J Med. 2003;348:2646-2655.
29. Faris JE, Moore AF, Daniels GH. Sunitinib (Sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007;17:1147-1149.
30. de Groot JW, Links TP, van der Graaf WT. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol. 2006;17:1719-1720.
31. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006; 290:H560-H576.
32. Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and the use of targeted therapy. Endocrinol Metab Clin North Am. 2007;36:839-853, viii.
33. ClinicalTrials.gov. Clinical trial number NCT00381641. Sunitinib in treating patients with thyroid cancer that did not respond to iodine I 131 and cannot be removed by surgery. Bethesda, MD: U.S. National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00381641?term= NCT00381641&rank=1. Accessed for verification August 1, 2008.
34. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer. 2007;96:16-20
35. Herbst R, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Invest Drugs. 2007;16:239-249.